Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass balance of talazoparib in advanced solid tumors
NCT03070548Phase 1Completed
- Sponsor
- Pfizer
- Start
- Sep 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talazoparib in solid tumor (advanced stage), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration at 504 hours, Time to Attain Maximum Observed Plasma Concentration at 504 hours and 9 more. Started Sep 2016; status: completed.
02
Drugs
talazoparib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03070548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03070548.